Akèy › Limfòm selil B › Missouri
Etid klinik pou Limfòm selil B nan Missouri
5 etid pou Limfòm selil B ap chèche patisipan nan sit nan Missouri.
Vil nan Missouri
Tèks ofisyèl etid la (Anglè)
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
- Washington University School of Medicine, St Louis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT06742996A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
- Washington University School of Medicine, St Louis
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 11, 2026 · NCT06634589A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies
- Washington University School of Medicine/Siteman Cancer Center, St Louis
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 17, 2026 · NCT06528301DALY II USA/ MB-CART2019.1 for DLBCL
- Washington University, St. Louis, St Louis
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jul 13, 2026 · NCT04792489A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
- Washington University, St Louis
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Nov 14, 2025 · NCT05643742Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.